Peripheral tolerance occurs in secondary lymphoid organs (i.e., lymph nodes and spleen) and regulates the activation of nave T-cells via two mechanisms: anergy and regulatory T-cells. Anergy ...

Explore how T cell engagers could transform cancer and autoimmune treatments through promising trials and key collaborations.

The FDA has accepted an investigational new drug application for ALLO-329, an allogeneic chimeric antigen receptor T-cell ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Developing effective treatments and understanding how the mechanism of the immune system have always been challenging for ...

A better understanding of inflammation and lung immunity over the past two decades has led to new, innovative treatments for ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...

Imagine a breakthrough in cancer treatment where only malignant cells are targeted, sparing healthy host cells; or patients with abnormal protein synthesis are treated to produce a healthy protein.

Scientists engineered T cells to protect instead of kill, potentially enabling targeted treatments for autoimmune disease and ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...

Researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin. One day, researchers want to use switches of this kind to ...

TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for ...